ARS Pharmaceuticals (SPRY) Other Non-Current Assets (2020 - 2026)

ARS Pharmaceuticals has disclosed Other Non-Current Assets across 7 years of filings, most recently posting $2.7 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $2.7 million, down 15.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 million (down 15.27% YoY), and the FY2025 annual result was $2.8 million, down 10.53% from the prior year.
• Other Non-Current Assets came in at $2.7 million for Q1 2026 at ARS Pharmaceuticals, down from $2.8 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $3.1 million in Q1 2025 to a low of $21000.0 in Q4 2023.
• The 5-year median for Other Non-Current Assets is $2.5 million (2022), against an average of $1.8 million.
• Across the five-year window, Other Non-Current Assets tumbled 99.29% in 2023 and soared 14728.57% in 2024, its largest moves.
• ARS Pharmaceuticals' Other Non-Current Assets stood at $2.9 million in 2022, then plunged by 99.29% to $21000.0 in 2023, then jumped by 14728.57% to $3.1 million in 2024, then slipped by 10.53% to $2.8 million in 2025, then declined by 4.77% to $2.7 million in 2026.
• The last three Other Non-Current Assets figures came in at $2.7 million (Q1 2026), $2.8 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.